Trial Profile
Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Gemcitabine; Oxaliplatin; Pegfilgrastim; Rituximab
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 19 May 2011 Planned End Date (1 Feb 2013) added as reported by ClinicalTrials.gov.
- 01 Mar 2011 New trial record